-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Since 2021, heavy policies to support the development of traditional Chinese medicine have been released frequently, driving the continuous increase in the attention of the sector
.
Since November, the traditional Chinese medicine sector has surged more than 7%
.
Among them, Yabao Pharmaceutical has several times of daily limit, and Guilin Sanjin, Longjin Pharmaceutical and other stocks have increased significantly more than the traditional Chinese medicine sector
.
At present, the popularity of the Chinese medicine sector is still unabated.
Recently, the news that a Chinese medicine medical and health service provider, Gushengtang, is about to be listed on the main board of the Hong Kong Stock Exchange has attracted widespread attention in the industry and attracted a number of large institutions.
Investors are heavy
.
It is reported that Gushengtang has recently completed its IPO and plans to issue 27.
878 million shares with a stock price ranging from 25.
8 yuan to 29 yuan.
It is expected to be officially listed on December 10, with Bank of America Merrill Lynch and Haitong International as its joint sponsors
.
According to the prospectus, Gushengtang has signed a cornerstone investment agreement
.
Cornerstone investors include Foresight Funds (Foresight Funds, wholly managed by Orient Asset Management (Hong Kong) Limited), Boyu, Sage Partners (managed by Foresight Capital Limited), and UBS AM Singapore, according to which cornerstone investors have a total of The relevant number of Offer Shares subscribed for an aggregate amount of US$42 million or approximately HK$356 million, representing approximately 42% of the Offer Shares
.
Based on the offer price of HK$27.
40 per offer share, which is the midpoint of the offer price range, the total number of shares to be subscribed by cornerstone investors is 11,897,800
.
It can be seen that the company has a high degree of recognition
.
According to the data, Gushengtang mainly provides TCM medical and health services and products to customers through offline medical institutions and online medical and health platforms to meet the diversified medical and health management needs of customers
.
In recent years, the company has actively followed the development trend of the Internet, and stood out in the traditional Chinese medicine health market through the integration of online and offline business, rich physician resources and stable supply chain
.
At present, the company operates a network covering 42 medical institutions in Beijing, Shanghai, Guangzhou, Shenzhen, Foshan, Zhongshan, Fuzhou, Nanjing, Suzhou, Ningbo and Wuxi
.
As of June 30, 2021, the company's cumulative number of customers was close to 1.
9 million, and the cumulative number of customer visits exceeded 8.
4 million on the same day
.
At the same time, Gushengtang’s revenue has also performed well in recent years
.
In 2018, 2019 and 2020, the company's revenue was 726 million yuan, 896 million yuan, and 925 million yuan, respectively, with a compound annual growth rate of 12.
9%.
In the first half of 2021, the company's revenue was 598 million yuan, a significant year-on-year increase.
78.
1%
.
However, the company is still losing money
.
In 2018, 2019 and 2020, Gushengtang lost 211 million yuan, 162 million yuan and 177 million yuan respectively
.
In the first half of 2021, Gushengtang lost 300 million yuan
.
The prospectus shows that providing medical and health solutions and selling medical and health products is the source of income for Gushengtang
.
Among them, the provision of medical and health solutions is the main source of income, accounting for more than 90% of the overall income
.
From the perspective of the industry, from the above data, Gushengtang's business model has high certainty, especially the business scale of Gushengtang provides it with a virtuous circle
.
On the one hand, the company has been deeply engaged in the field of traditional Chinese medicine services for many years, and the company has established a high-quality team of traditional Chinese medicine, and the service quality has been continuously recognized, with a growing patient group
.
On the other hand, the stable business flow and data generated by the company's customers, as well as the number of patient visits, provide the company with greater brand influence and pricing flexibility, which is conducive to the company's further improvement of its core competitiveness and the ability to serve patients.
Entering the next cycle, it is expected that the company's future growth rate will be considerable and certain
.
.
Since November, the traditional Chinese medicine sector has surged more than 7%
.
Among them, Yabao Pharmaceutical has several times of daily limit, and Guilin Sanjin, Longjin Pharmaceutical and other stocks have increased significantly more than the traditional Chinese medicine sector
.
At present, the popularity of the Chinese medicine sector is still unabated.
Recently, the news that a Chinese medicine medical and health service provider, Gushengtang, is about to be listed on the main board of the Hong Kong Stock Exchange has attracted widespread attention in the industry and attracted a number of large institutions.
Investors are heavy
.
It is reported that Gushengtang has recently completed its IPO and plans to issue 27.
878 million shares with a stock price ranging from 25.
8 yuan to 29 yuan.
It is expected to be officially listed on December 10, with Bank of America Merrill Lynch and Haitong International as its joint sponsors
.
According to the prospectus, Gushengtang has signed a cornerstone investment agreement
.
Cornerstone investors include Foresight Funds (Foresight Funds, wholly managed by Orient Asset Management (Hong Kong) Limited), Boyu, Sage Partners (managed by Foresight Capital Limited), and UBS AM Singapore, according to which cornerstone investors have a total of The relevant number of Offer Shares subscribed for an aggregate amount of US$42 million or approximately HK$356 million, representing approximately 42% of the Offer Shares
.
Based on the offer price of HK$27.
40 per offer share, which is the midpoint of the offer price range, the total number of shares to be subscribed by cornerstone investors is 11,897,800
.
It can be seen that the company has a high degree of recognition
.
According to the data, Gushengtang mainly provides TCM medical and health services and products to customers through offline medical institutions and online medical and health platforms to meet the diversified medical and health management needs of customers
.
In recent years, the company has actively followed the development trend of the Internet, and stood out in the traditional Chinese medicine health market through the integration of online and offline business, rich physician resources and stable supply chain
.
At present, the company operates a network covering 42 medical institutions in Beijing, Shanghai, Guangzhou, Shenzhen, Foshan, Zhongshan, Fuzhou, Nanjing, Suzhou, Ningbo and Wuxi
.
As of June 30, 2021, the company's cumulative number of customers was close to 1.
9 million, and the cumulative number of customer visits exceeded 8.
4 million on the same day
.
At the same time, Gushengtang’s revenue has also performed well in recent years
.
In 2018, 2019 and 2020, the company's revenue was 726 million yuan, 896 million yuan, and 925 million yuan, respectively, with a compound annual growth rate of 12.
9%.
In the first half of 2021, the company's revenue was 598 million yuan, a significant year-on-year increase.
78.
1%
.
However, the company is still losing money
.
In 2018, 2019 and 2020, Gushengtang lost 211 million yuan, 162 million yuan and 177 million yuan respectively
.
In the first half of 2021, Gushengtang lost 300 million yuan
.
The prospectus shows that providing medical and health solutions and selling medical and health products is the source of income for Gushengtang
.
Among them, the provision of medical and health solutions is the main source of income, accounting for more than 90% of the overall income
.
From the perspective of the industry, from the above data, Gushengtang's business model has high certainty, especially the business scale of Gushengtang provides it with a virtuous circle
.
On the one hand, the company has been deeply engaged in the field of traditional Chinese medicine services for many years, and the company has established a high-quality team of traditional Chinese medicine, and the service quality has been continuously recognized, with a growing patient group
.
On the other hand, the stable business flow and data generated by the company's customers, as well as the number of patient visits, provide the company with greater brand influence and pricing flexibility, which is conducive to the company's further improvement of its core competitiveness and the ability to serve patients.
Entering the next cycle, it is expected that the company's future growth rate will be considerable and certain
.
